Bacillus Calmette Guerin

BIOLOGICAL4 trials

Sponsors

Jørgen Bjerggaard Jensen, University of Campinas, Brazil, ECOG-ACRIN Cancer Research Group, Assiut University

Conditions

Bacillus Calmette-GuerinBladder CancerNon-muscle-invasive Bladder CancerSide Effect of DrugSperm Count, LowTestis; FibrosisUrothelial Carcinoma Bladder

Phase 3

Immunological Response of Bladder Cancer Patients Under BCG

CompletedNCT04806178

University of Campinas, BrazilBacillus Calmette-Guerin, Bladder Cancer

Start: 2021-09-03End: 2024-08-18Updated: 2024-12-09

Intravesical BCG vs GEMDOCE in NMIBC

Active, not recruitingNCT05538663

ECOG-ACRIN Cancer Research GroupNon-muscle-invasive Bladder Cancer

Start: 2023-02-07End: 2030-10-01Target: 870Updated: 2026-09-15

Phase 4

NORTH-REG Dwell-Time Study

Active, not recruitingNCT04701151

Jørgen Bjerggaard JensenSide Effect of Drug

Start: 2021-02-03End: 2030-12-01Target: 314Updated: 2026-03-03

Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume

Assiut UniversitySperm Count, Low, Testis; Fibrosis, Urothelial Carcinoma Bladder

Start: 2023-04-01End: 2025-12-31Target: 25Updated: 2023-01-27

Related Papers

Artificial intelligence for predicting BCG response in non-muscle-invasive bladder cancer: a systematic review.

2026-08-17

Symptom‐guided reduction of <scp>BCG</scp> dwell time: findings from the north‐ <scp>REG</scp> randomized trial

British Journal of Urology2026-07-31

Intradermal priming to intravesical Bacillus Calmette-Guérin in non-muscle invasive bladder cancer: A translational research and phase I clinical trial.

2025-05-291 citations